Welcome to FiercePharma

Noted from the publisher 

Welcome to the inaugural issue of FiercePharma. We know your time is at a premium and we're honored that you have welcomed us into your inbox.

FiercePharma will be a concise look at the companies, news and trends shaping the pharmaceutical industry. We'll pay specific attention to the market development of approved products along with detailed updates on the inner workings at the FDA. You'll also find additional coverage on specific topics such as the changing landscape of generic drugs, pharmaceutical sales and marketing news, manufacturing issues, and much more.

We hope you find this coverage to be valuable and an indispensable part of your day. If you ever have any comments, questions, or suggestions to improve the publication, please send me a note. We are excited to welcome you to the Fierce community.

Best,

Sean Griffey
Publisher, FiercePharma
[email protected]

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.